Gilead Sciences
GILD
$1.71 (-1.36%)
1D
1W
3M
1Y
5Y
ALL
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Forbes • 10 hours ago • GILD
The Healthcare M&A Wave
Zacks Investment Research • 1 day ago • GILD
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
Zacks Investment Research • 2 days ago • GILD
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
Business Wire • 2 days ago • GILD
U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Business Wire • 6 days ago • GILD
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.